New Zealand’s Commerce Commission has announced a probe into the nation’s pharmaceutical industry. While the Commission had originally ordered changes on the Community Pharmacy Services Agreement last July, the authority is now looking into whether certain clauses in that agreement were created in an attempt to fix prices of prescription medications. According to reports, the agreement prohibited the act of discounting prescription drugs at pharmacies. When the clause was contested by a pharmacy owner, the Commission removed the clauses last December on the basis the agreement was anticompetitive. Now, according to the authority, DHB Shared Services, which added the clauses, as well as the organizations that supported it, are now under investigation.
Featured News
Jury in Boston Set to Decide Takeda’s Fate in Amitiza Antitrust Trial
May 14, 2026 by
CPI
OnlyFans Faces New Antitrust Lawsuit
May 14, 2026 by
CPI
Americans’ Opposition to Hosting AI Data Centers Hardens, Survey Finds
May 14, 2026 by
CPI
NextEra Energy Agrees to $9.5 Million Settlement in Nuclear Industry Wage-Fixing Case
May 14, 2026 by
CPI
South Korea’s Antitrust Agency Raids Petrochemical Firms in Price-Fixing Probe
May 14, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Unilateral Effects
Apr 28, 2026 by
CPI
A Net Present Value Approach to Merger Analysis
Apr 28, 2026 by
Joseph J Simons & Malcolm Coate
Generative AI and Competitive Disruption: Increasingly Relevant for Merger Analysis?
Apr 28, 2026 by
Andrea Coscelli, Emily Chissell, Nitika Bagaria & Tega Akati-Udi
Non-Price Unilateral Effects In Media Mergers
Apr 28, 2026 by
Lapo Filistrucchi & Teresa Oriani
Ecosystem Mergers and Unilateral Effects? A Framework for Assessing the Ecosystem Theory of Harm
Apr 28, 2026 by
Ethel Fonseca, George Tucker & Helder Vasconcelos